Expert panel approves use of Serum Institute's Covovax for 7-11-year olds

India started vaccinating adolescents (aged 15-18) from January, and further expanded the drive to include children as young as 12 years from March

vaccine
The expert panel had recommended use of Corbevax for children as young as five in April, while it had sought more data from Bharat Biotech for kids in the 2-11-year category
Sohini Das Mumbai
2 min read Last Updated : Jun 25 2022 | 12:59 AM IST
An expert panel advising the Central Drugs Standard Control Organisation (CDSCO) has recommended granting emergency use authorisation (EUA) to Serum Institute of India’s (SII’s) Covovax for use in children aged 7-11, according to sources. 

The Drugs Controller General of India (DCGI) will review this recommendation before granting a final approval. 

Sources indicated that the SEC deliberated upon the matter and recommended an EUA for use in younger children. The process of data review was on for the past few months, after SII submitted trial data from their children’s studies around March.

Covovax — the protein vaccine from US major Novovax — already has DCGI nod for use in adults as well as children in the age group of 12-17 years. The government has procured Biological E’s vaccine Corbevax for adolescent vaccination, and has not placed orders for Covovax. Bharat Biotech’s Covaxin, too, has approval for use for 12-17-year olds. 

The expert panel had recommended use of Corbevax for children as young as five in April, while it had sought more data from Bharat Biotech for kids in the 2-11-year category. 

India started vaccinating adolescents (aged 15-18) from January, and further expanded the drive to include children as young as 12 years from March. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineVaccinationSerum InstituteSerum Institute of India

Next Story